Back

Effect of human synovial fluid from osteoarthritis patients and healthy individuals on lymphatic contractility

Michalaki, E.; Nepiyushchikh, Z. V.; Bernard, F. C.; Rudd, J. M.; Mukherjee, A.; McKinney, J. M.; Doan, T. N.; Willett, N. J.; Dixon, J. B.

2020-12-03 bioengineering
10.1101/2020.12.02.408294 bioRxiv
Show abstract

The lymphatic system has been proposed to play a crucial role in the development and progression of osteoarthritis (OA). The synovial fluid (SF) of arthritic joints contains mediators of the inflammatory response and products of the injury to articular tissues, while lymphatic system plays a critical role in resolving inflammation and overall joint homeostasis. Despite the importance of both the lymphatic system and SF in OA disease, their relationship is still poorly understood. Here, we utilized SF derived from osteoarthritis patients (OASF) and healthy individuals (HSF) to investigate potential effects of SF on migration of lymphatic endothelial cells (LECs) in vitro, and lymphatic contractility of femoral lymphatic vessels (LVs) ex vivo. Both OASF and HSF treatments led to an increased migratory response in vitro compared to LECs treatment with media without serum. Ex vivo, both OASF and HSF treatments to the lumen of isolated LVs led to significant differences in the tonic and phasic contractions and these observations were dependent on the SF treatment time. Specifically, OASF treatment transiently enhanced the RFLVs tonic contractions. Regarding the phasic contractions, OASF generated either an abrupt reduction after 1 hr of treatment or a complete cease of contractions after an overnight treatment, while HSF treatment displayed a gradual decrease in lymphatic contractility. The observed variations after SF treatments suggest that the pump function of lymphatic vessel draining the joint could be directly compromised in OA and thus might present a new therapeutic target.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Osteoarthritis and Cartilage
30 papers in training set
Top 0.1%
19.4%
2
International Journal of Molecular Sciences
453 papers in training set
Top 0.4%
7.1%
3
Journal of Orthopaedic Research
19 papers in training set
Top 0.1%
6.6%
4
The FASEB Journal
175 papers in training set
Top 0.1%
5.0%
5
Scientific Reports
3102 papers in training set
Top 26%
4.5%
6
PLOS ONE
4510 papers in training set
Top 36%
4.0%
7
eLife
5422 papers in training set
Top 29%
3.2%
8
Frontiers in Immunology
586 papers in training set
Top 3%
2.4%
50% of probability mass above
9
PeerJ
261 papers in training set
Top 6%
1.8%
10
Journal of Biological Engineering
10 papers in training set
Top 0.1%
1.7%
11
Journal of Biomedical Materials Research Part A
18 papers in training set
Top 0.2%
1.7%
12
Journal of Biomechanical Engineering
17 papers in training set
Top 0.2%
1.4%
13
Advanced Therapeutics
15 papers in training set
Top 0.2%
1.4%
14
Frontiers in Cellular and Infection Microbiology
98 papers in training set
Top 4%
1.3%
15
Frontiers in Physiology
93 papers in training set
Top 4%
1.3%
16
Frontiers in Pharmacology
100 papers in training set
Top 3%
1.3%
17
iScience
1063 papers in training set
Top 23%
1.1%
18
Frontiers in Oncology
95 papers in training set
Top 3%
1.0%
19
Disease Models & Mechanisms
119 papers in training set
Top 2%
1.0%
20
Arthritis Research & Therapy
15 papers in training set
Top 0.2%
0.9%
21
Stem Cell Research & Therapy
30 papers in training set
Top 0.6%
0.9%
22
Advanced Science
249 papers in training set
Top 16%
0.9%
23
Pharmaceuticals
33 papers in training set
Top 1%
0.8%
24
Journal of The Royal Society Interface
189 papers in training set
Top 4%
0.8%
25
ACS Omega
90 papers in training set
Top 4%
0.8%
26
Frontiers in Aging Neuroscience
67 papers in training set
Top 3%
0.8%
27
Progress in Neurobiology
41 papers in training set
Top 2%
0.8%
28
Experimental Eye Research
30 papers in training set
Top 0.5%
0.7%
29
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 9%
0.7%
30
Communications Biology
886 papers in training set
Top 28%
0.7%